In vitro synergistic effects of some novel Cu(II) complexes in combination with epirubicin and mitomycin C against HeLa-S3 cervical cancer cell line.
The in vitro predictive chemosensitivity of a HeLa-S3 human cervical cancer cell line to a new series of Cu(II) complexes as well as their combination with several chemotherapeutic drugs was determined. Antiproliferative activity was evaluated by the XTT assay. Among all tested drugs, HeLa-S3 cells were especially sensitive to epirubicin (EPR) or mitomycin C (MMC) antitumor agents. The combination of EPR or MMC with the complexes resulted in a pronounced synergistic amplification of their antiproliferative effect. This marked synergism was observed in all drug combinations.
Geromichalos
G D
GD
Research Department, Theagenion Cancer Institute, Thessaloniki, Greece.
Katsoulos
G A
GA
Hadjikostas
C C
CC
Kortsaris
A H
AH
Kyriakidis
D A
DA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001761:Bleomycin / Q000008:administration & dosage; D002455:Cell Division / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage; D003300:Copper / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004357:Drug Synergism; D015251:Epirubicin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006367:HeLa Cells; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage; D009942:Organometallic Compounds / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D009942:Organometallic Compounds; D001761:Bleomycin; D015251:Epirubicin; D016685:Mitomycin; D014750:Vincristine; D003300:Copper; D003520:Cyclophosphamide; D002945:Cisplatin; D005472:Fluorouracil